Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Impatients

Status

Conditions: Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV; Pancreas Cancer; Pancreatic Cancer

Treatments: Biological: IMM-101

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04137822

2019-IMM101IMM-EU

Details and patient eligibility

About

An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.

Full description

IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms.

Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.

Exclusion criteria

Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).